BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12735499)

  • 1. The natural history of prostate cancer.
    Kessler B; Albertsen P
    Urol Clin North Am; 2003 May; 30(2):219-26. PubMed ID: 12735499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
    J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
    Zietman AL; Thakral H; Wilson L; Schellhammer P
    J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adenocarcinoma of the prostate].
    Dvorácek J
    Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
    Adolfsson J; Tribukait B; Levitt S
    Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.
    Wilt TJ
    Semin Urol Oncol; 2002 Feb; 20(1):10-7. PubMed ID: 11828353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of prostate cancer in elderly Japanese patients 80 years of age or older.
    Suzuki H; Akakura K; Ueda T; Mikami K; Tobe T; Komiya A; Ichikawa T; Igarashi T; Ito H
    Eur Urol; 2002 Feb; 41(2):172-7. PubMed ID: 12074405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
    Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
    Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.
    Khan MA; Han M; Partin AW; Epstein JI; Walsh PC
    Urology; 2003 Jul; 62(1):86-91; discussion 91-2. PubMed ID: 12837428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomograms for clinically localized disease. Part III: watchful waiting.
    Schwartz E; Albertsen P
    Semin Urol Oncol; 2002 May; 20(2):140-5. PubMed ID: 12012300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
    McLaren DB; McKenzie M; Duncan G; Pickles T
    Cancer; 1998 Jan; 82(2):342-8. PubMed ID: 9445192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
    Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
    Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor.
    Koppie TM; Grossfeld GD; Miller D; Yu J; Stier D; Broering JM; Lubeck D; Henning JM; Flanders SC; Carroll PR
    J Urol; 2000 Jul; 164(1):81-8. PubMed ID: 10840429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
    Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
    BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic features in men who died of prostate cancer.
    Thompson KE; Hernández J; Canby-Hagino ED; Troyer D; Thompson IM
    J Urol; 2005 Aug; 174(2):553-6; discussion 556. PubMed ID: 16006890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.